intellectual property / patents

Cytopia has a strong and growing intellectual property platform based on:

Targets
Exclusive worldwide license to several granted patents on validated drug targets-JAK1 and JAK2 kinases.

Mechanisms
A family of patent applications covering a novel mechanism of kinase inhibition.

Novel  chemicals
A suite of patent applications claiming novel kinase and tubulin inhibitors as new chemical entities. These applications are progressing at various stages. Patents have been issued or granted in countries including the U.S.A., the U.K., Europe, China, India and Australia.

Therapeutic applications

Patent applications covering use of kinase inhibitors in new indications.

Techniques
Proprietary software platform - ChemaPhore™ for in silico drug design and screening